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The ﬁeld of automated patch-clamp electrophysiology has emerged from the tension
between the pharmaceutical industry’s need for high-throughput compound screening ver-
sus its need to be conservative due to regulatory requirements. On the one hand, hERG
channel screening was increasingly requested for new chemical entities, as the correla-
tion between blockade of the ion channel coded by hERG and torsades de pointes cardiac
arrhythmia gained increasing attention. On the other hand, manual patch-clamping, typi-
cally quoted as the “gold-standard” for understanding ion channel function and modulation,
was far too slow (and, consequently, too expensive) for keeping pace with the numbers of
compounds submitted for hERG channel investigations from pharmaceutical R&D depart-
ments. In consequence it became more common for some pharmaceutical companies
to outsource safety pharmacological investigations, with a focus on hERG channel interac-
tions.This outsourcing has allowed those pharmaceutical companies to build up operational
ﬂexibility and greater independence from internal resources, and allowed them to obtain
access to the latest technological developments that emerged in automated patch-clamp
electrophysiology – much of which arose in specialized biotech companies. Assays for
nearly all major cardiac ion channels are now available by automated patch-clamping using
heterologous expression systems, and recently, automated action potential recordings
from stem-cell derived cardiomyocytes have been demonstrated. Today, most of the large
pharmaceutical companies have acquired automated electrophysiology robots and have
established various automated cardiac ion channel safety screening assays on these, in
addition to outsourcing parts of their needs for safety screening.
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ION CHANNEL ACTIVITY DETERMINES ECG-DETECTABLE
CARDIOVASCULAR RISK
The coordinated electrical activity of the heart determines its abil-
ity to beat andpumpoxygenated blood successfully, and the overall
electrical activity is determined by the cellular action potentials
(APs) at the level of the cardiomyocyte. Ion channels mediate
transmembrane currents controlling the duration of cardiomy-
ocyte APs, which en masse can be detected at the skin via the
electrocardiogram (ECG; Sanguinetti and Tristani-Firouzi, 2006;
Witchel, 2011). The QT interval, which is measured as an in vivo
ECG parameter, has been shown to be an imperfect surrogate
marker for arrhythmogenic risk (Roden et al., 1996; Witchel
et al., 2003; Hondeghem, 2006). If prolonged in the presence of a
drug, it may indicate that a compound could cause acquired long
QT syndrome (aLQTS), and thus have a cardiac safety liability
(Roden, 2004). aLQTS is a potentially fatal drug-induced disor-
der associated with the risk of sudden cardiac death mediated by
the polymorphic ventricular tachyarrhythmia torsades de pointes
(TdP; Viskin, 1999). In many cases the pathophysiological basis
of aLQTS is based on a drug (or combination of drugs) interfer-
ing with the activity or production of either one or a range of
ion channels; thus, the testing of drugs for effects on ion channels
has become a major concern (and industry) within drug develop-
ment (Brown, 2008). For drug development programs that must
establish cardiac safety proﬁles to achieve regulatory approval, the
QT interval, therefore, remains one of the most important ECG
parameters.
Control of the duration of the cardiac ventricular AP is medi-
ated by the equilibrium between inward and outward currents
across the cell membrane (Carmeliet, 1993). Under physiological
conditions theAPprogresses through the phases of depolarization,
plateau phase, and repolarization over the course of 200–300ms,
but in LQTS repolarization is delayed and theAP duration at times
will be substantially prolonged. Electrophysiologically, this delay
in repolarization implies a deviation from the usual balance of
currents across the myocyte membrane responsible for normal
repolarization. Thus, prolongation of the AP could theoretically
arise from an increase in inward (depolarizing) current, or alter-
natively, from a decrease in outward (repolarizing) current carried
by potassium ions. Both of these conditions have been found to
exist as the genetic basis of pathology in various familial LQTS
patients (Splawski et al., 2000).
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Potassium channels play prominent roles in AP repolariza-
tion, as well as during the plateau phase. The rate of net K+
efﬂux, and by extension the rate of repolarization, is determined
by the density and gating properties of different K+ channels.
K+ channels mediating an inwardly rectifying current (IK1) are
important in maintaining the normal resting potential of ven-
tricular cardiomyocytes, and during the ﬁnal stage of AP repolar-
ization (Carmeliet, 1993). A rapidly activating and inactivating
transient outward current (I to) contributes to early AP repo-
larization and underlies the initial “notch” before the plateau
phase. Of particular relevance to the AP plateau is the delayed
rectiﬁer current (IK) comprised of rapid (IKr) and slow (IKs)
components mediated by distinct channel subtypes with distinct
kinetic properties (Sanguinetti and Jurkiewicz, 1990; Sanguinetti
and Keating, 1997). IK develops gradually during the plateau
phase, opposing the inward currents underlying sustained depo-
larization. As the net balance of current alters, and net outward
current exceeds inward current, repolarization occurs. IK and IK1
can be considered to regulate ventricular AP repolarization over
the plateau range, and ﬁnal rapid repolarization phase, respec-
tively (Sanguinetti and Keating, 1997). A schematic showing the
ventricular AP and the currents that comprise it are shown in
Figure 1.
The cellular electrophysiological testing of drugs for cardiac
safety tends to involve cardiac potassium channels, the cardiac
sodium channel and the l-type calcium channel, because the
association of these channels with LQTS is well-established. The
protein comprising the pore of IKr is made from four hERG1a
alpha subunits, and when these are expressed heterologously, the
channel mediating the resulting transmembrane current is com-
monly referred to as the hERG channel. The hERG channel is the
most commonly tested ion channel for cardiac liability of new
drugs. Other ion channels that are relevant to the cardiac AP
(Figure 1) are also tested commercially, including IKs (the slow
component of the delayed rectiﬁer current in cardiac myocytes),
IK1 (the inward component), IKur (the ultra rapid component),
IKto (the transient outward component), and I f (the “funny cur-
rent”). Sympathetic inﬂuences also affect arrhythmogenic risk,and
β-adrenergic effects (using GPCR-screening methods) can thus
also be tested for.
The most notorious ion channel associated with an aLQTS lia-
bility is the hERG (originally named human Ether-à-go-go related
gene, also now known as Kv11.1) potassium (K+) channel; the
reason so many drugs were linked to aLQTS mediated by hERG is
presumed to be due to the structure of the channel’s inner cavity,
which allows the channel to make promiscuous interactions with
many different small molecules (Mitcheson, 2008). Mutations in
this alpha subunit were initially shown to be the cause of genetic
long QT syndrome, and it was proposed that iatrogenic inhibition
of the channel could lead to pathology by failing to protect against
calcium-induced early after depolarizations (EADs) that could ini-
tiate arrhythmogenic electrical activity (January and Moscucci,
1992; Curran et al., 1995; Sanguinetti et al., 1995; Sanguinetti and
Keating, 1997).
For many years the only test of drug-induced channel blockade
that was viewed as critical for cardiac safety by drug regulators was
for hERG (Committee for Proprietary Medicinal Products, 1997),
FIGURE 1 | Ionic activity during the cardiac ventricular action potential.
(A) An idealized ventricular action potential (AP) is shown in the top panel;
the upward slope represents depolarization (positive voltages), and the
downward slope repolarization (negative voltages). Arrows indicate the
effects of the dominant currents on the potential: during the plateau phase,
depolarizing calcium currents, and repolarizing potassium currents balance
each other. (B)The main transmembrane ionic currents contributing to the
AP over time; inward (depolarizing) currents are shown below each axis,
and outward (repolarizing) currents are shown above each axis. Relative
polarities and time courses are indicated; relative amplitudes are not to
scale. IKr Rapid delayed rectiﬁer current. Adapted with permission from
Witchel (2011).
despite the fact that an ensemble of currents contributes to the
AP (and the ECG). It is generally understood that changing the
activity of ion channels on the cell surface of cardiac myocytes can
both contribute to arrhythmogenesis and to its amelioration (Bril
et al., 1996; ICH, 2005; Hansen et al., 2007), and that although
blockade of hERG may increase the substrate for arrhythmoge-
nesis, that concurrent blocking of L-type calcium channels may
serve to reduce EADs and the arrhythmogenic substrate (Janu-
ary and Riddle, 1989; Bril et al., 1998; Chouabe et al., 1998). A
number of investigators pointed out that extrapolating the net
drug-induced effects on a range of channels based on measuring
only one type of current can give false picture (Witchel et al., 2003).
The pharmaceutical industry is therefore concerned with develop-
ing in vitro cardiac safety assays that provide an early measure of
cardiac safety, integrating more than only the hERG ion channel
current (Moeller, 2011).
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AUTOMATED PATCH-CLAMP ELECTROPHYSIOLOGY
ALLEVIATES A BOTTLENECK IN CARDIAC ION CHANNEL
SAFETY SCREENING
AUTOMATED PATCH-CLAMP ELECTROPHYSIOLOGY PROVIDES A
DIRECT BIOPHYSICAL READOUT OF ION CHANNEL FUNCTION
The ﬂux of ions through transmembrane channels is accom-
panied by a charge transfer across the biological membrane.
This charge transfer can be measured by biophysical readouts,
and the manual patch-clamp technique (Neher and Sakmann,
1976; Hamill et al., 1981) is typically referred to as the “gold-
standard” method for achieving this. Attempts to automate and
simplify the classical, relatively slow, and technically challeng-
ing patch-pipette-based approach unfolded at NeuroSearch in
the late 1990s with the development of NeuroPatch, later intro-
duced as Apatchi-1 (Asmild et al., 2003). Subsequently, a few
other systems have been developed that automate the classi-
cal method of pipette-based patch-clamping; however, none of
these appear to have yielded a major revolution in patch-clamp
throughput.
The technical realization that cells could form high-resistance
(gigaseal) connections to planar glass substrates allowed for
the introduction of chip-based systems for automated patch-
clamp electrophysiology. This ﬁnding, approximately 10 years
ago (Fertig et al., 2001, 2002; Sigworth and Klemic, 2002), has
allowed scientists to increase the throughput of automated patch-
clamping to the next level, and has started a technological rev-
olution that alleviated the major bottleneck of throughput in
ion channel patch-clamp research. A couple of biotech startup
companies were launched and then contributed to bringing this
(or a closely related) new technology to the market [including
Nanion Technologies GmbH, Munich; Cytocentrics AG, Ros-
tock; Flyion GmbH, Tübingen; Essen Instruments (now Essen
BioScience, Inc.), Cytion SA (Lausanne, acquired by Molecular
Devices, LLC); Cellectricon AB (Mölndal); Sophion A/S (Copen-
hagen); Fluxion LLC (San Francisco)], and the technology was
also a part of development activities in established companies
[especially Axon Instruments, now part of Molecular Devices, LLC
(MDS)].
THE REQUIREMENT FOR HERG CHANNEL DATA FOSTERED THE
DEVELOPMENT OF AUTOMATED PATCH-CLAMP ROBOTS
Around the beginning of this century, awareness for the relevance
of a blockade of the cardiac hERG ion channel for the develop-
ment of drug-induced cardiac arrhythmias arose and was reﬂected
in regulatory guidelines (ICH S7A, ICH S7B). Consequently the
pharmaceutical industry was in huge need of hERG channel safety
screening data of new drug candidates. A couple of small and
medium-sized university spin-offs and biotech companies started
to offer this kind of investigations for pharmaceutical compa-
nies, by employing different technologies: high-throughput assays
(e.g., Fluorescence, binding, or ﬂux assays: these represent an indi-
rect readout, but are relatively cheap and offer a relatively high
throughput), or manual patch-clamp assays (with only low com-
pound throughput, and consequently at relatively high costs per
data point). Some of these companies presented a showcase for
a time-matched introduction of a scientiﬁcally sound and highly
relevant expert service, which the pharmaceutical industry was
in dire need of, and which in some cases developed into a great
commercial success. With increasing demand for hERG channel
data, it is not surprising that the hERG ion channel was one of
the ﬁrst channels for which an assay was established on the newly
developed automated patch-clamp instruments (Kiss et al., 2003),
and in turn the need for high-throughput hERG channel patch-
clamp data was a major accelerator in the further advancement of
automated patch-clamp robots.
PROTOCOLS FOR AUTOMATED PATCH-CLAMP ASSAYS NEED TO BE
CAREFULLY SET UP AND VALIDATED
Patch-clamp robots available today typically employ planar sub-
strates onwhich cells delivered from suspension can formgigaseals
(for an excellent review on automated patch-clamp instruments,
see Dunlop et al., 2008). Protocols and details for the investiga-
tion of a number of different cell types by automated patch-clamp
are given in the excellent paper by Milligan et al. (2009). Since its
ﬁrst application to measuring the hERG channel for safety screen-
ing (Kiss et al., 2003), this technique has been well validated for
a number of robots. It is now widely applied to reduce the lia-
bility of compound series’ towards the hERG channel as part of
safety pharmacology assessment early during medicinal chemistry
compound development (Kutchinsky et al., 2003; Davenport et al.,
2010; Riether et al., 2011; Tye et al., 2011). Reported correlations
of biophysical channel properties (Figure 2) as well as phar-
macological compound properties between automated (planar,
chip-based) and manual (pipette-based) patch-clamp investiga-
tions are generally excellent (Kutchinsky et al., 2003; Xu et al.,
2003; Tao et al., 2004; Bridgland-Taylor et al., 2006; Jones et al.,
2009;Davenport et al., 2010;Golden et al., 2011). The reported dis-
crepancies between manual and automated patch-clamping have
been well investigated, and a number of reasons for reported dis-
crepancies have been identiﬁed. It is important to note that all of
these reported discrepancies are not attributed to the technologi-
cal principle of chip-based patch-clamping. Rather, one or several
of the following points have been identiﬁed as the major source of
potential discrepancies (Mathes, 2006; Ly et al., 2007; Farre et al.,
2009; Mo et al., 2009; Davenport et al., 2010; Moller and Slack,
2010) if automated patch-clamp assays are not well validated: (1)
Platematerial in automated robots: inmanual patch-clamping, test
solutions are typically prepared in relatively large quantities and
are continuously perfused, while in automated robots, microtiter
plates with a smaller volume are used, and relatively small volumes
of test solutions are added (one or several times) to the patched
cells. The unfavorable surface-to-volume ratio in microtiter plates
can lead to a potential reduction of compound concentrations
in automated patch-clamping, especially if a hydrophobic plate
material is employed. This would lead to a shift of IC50 curves to
larger nominal compound concentrations. It has therefore become
good practice to use glass plates in automated electrophysiology
robots, in particular for all aqueous solutions. In this context it
is important to also consider the material of the patch-clamp
chip. (2) Timing of compound preparation: in manual patch-
clamp experiments, it is relatively easy to prepare test solutions
directly before the patch-clamp experiment. This time-matched
preparation of test solutions can become a challenge in automated
experiments, due to the higher throughput, and the corresponding
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FIGURE 2 | Representative hERG channel whole-cell current–voltage
relationships by manual and automated patch-clamp electrophysiology
from CHO cells stably expressing the channel.The characteristic
bell-shaped current–voltage relation can be clearly seen during both partial
repolarization phases [different current–voltage protocols for recording hERG
channel currents have been described in the literature (e.g., Hancox et al.,
1998; Su et al., 2004, 2009; Deisemann et al., 2008)]. (A) Recorded by
manual patch-clamp using the following stimulation protocol: cells were held
at −80mV, depolarized to +20mV for 1 s, and repolarized in steps from −120
to +40mV in 10mV intervals for 1 s each. Stimulation frequency was 0.1Hz.
(B) Recorded by automated planar patch-clamp on the Patchliner (Nanion
Technologies) using the following stimulation protocol: cells were held
at −80mV, depolarized to +40mV for 500ms, and repolarized in steps from
−140 to +40mV in 20mV intervals for 500ms each. Stimulation frequency
was 0.1Hz. Adapted with permission from Moeller (2010). For more
experimental details see Davenport et al. (2010).
requirement of a larger number of different test solutions. A time
lag between the preparation of test solutions and the experiment
can however result in a precipitation of compounds in test solution
over time, resulting in IC50 curves shifted to larger nominal com-
pound concentrations. (3) Buffer compositions: the ionic strength
of buffers can shift pharmacological proﬁles of compounds (e.g.,
different ions can have an effect on channel gating, and certain
compounds interact preferably with certain states of the channel).
Consequently, it appears advisable to use buffers that mimic physi-
ological conditions as closely as possible. (4) It is important to note
that also manually measured compound IC50 values often span a
relatively large range between different labs, often owing to differ-
ent voltage protocols that are applied, or to different experimental
temperatures.
Technological developments have further increased the
throughput of automated patch-clamp robots during the past
years. This has happenedon the onehandby increasing paralleliza-
tion of measurement electrodes, thereby allowing the execution
of more patch-clamp recordings in parallel in one experimental
run. In a different approach, it has been shown that an increased
experiment success rate could be reached if seals with reduced
resistance are included into the data evaluation. This notion has
allowed reducing the technological demands for controlled seal
formation, and has thereby facilitated an even higher rate of par-
allelization, albeit at potentially reduced data quality owing to
the lack of high-resistance gigaseals. Interestingly, the develop-
ment of ensemble patch-recordings (Finkel et al., 2006), as used
in various of today’s instruments, averages out biological vari-
ability of individual cells, and thereby increases data consistency
and reproducibility even in low-resistance experiments for most
cell systems and ion channels (Finkel et al., 2006; Cao et al.,
2010).
AUTOMATED PATCH-CLAMP ASSAYS GO BEYOND hERG
Most of the relevant cardiac ion channel safety targets that are dis-
cussed above have been shown to be amenable to measurements
ondifferent electrophysiological platforms inheterologous expres-
sion systems (Wible et al., 2008;Balasubramanian et al., 2009; Farre
et al., 2009; Cao et al., 2010; Penniman et al., 2010), and form a
standard resource within safety departments of many pharma-
ceutical companies. In addition, a number of competitive special-
ized Biotech Contract Research Organizations (CRO) are offering
investigations of cardiac (and other) ion channels using well vali-
dated automated patch-clamp electrophysiology assays under fee-
for-service or alliance contract agreements (e.g., Chantest, OH,
USA; Millipore, MA, USA (now part of Merck KGaA); Aviv-
aBioSciences, California; Evotec AG, Hamburg). Thereby these
companies are offering an established ﬂexible resource to meet
outsourcing requirements of the pharmaceutical and the biotech
industry.
It has been described that some compounds are more potent
hERG-inhibitors at physiological temperature as compared to
room temperature: measurements at the (higher) physiological
temperature might affect the IC50s for the many open-state hERG
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channel blockers (e.g., methanesulfonanilides), as the faster kinet-
ics at the higher temperature would make more of the channel
available for open-state blockade (Zhou et al., 1998). This is
especially relevant for safety investigations, where compounds
could be incorrectly classiﬁed as non-hERG active if they are inves-
tigated at room temperature. It has therefore become goodpractice
to perform hERG investigations (especially the relatively late-stage
GLP) at (or near) physiological temperature. While the ﬁrst auto-
mated patch-clamp instruments were only capable of operating
at room temperature, some manufacturers of automated patch-
clamp equipment have responded to this need for automated
patch-clamp investigations at (or near) physiological temperature
(Farre et al., 2007; Golden et al., 2011).
AUTOMATED PATCH-CLAMPING OF CARDIOMYOCYTES PROVIDES
PHYSIOLOGICALLY RELEVANT ACTION POTENTIAL DATA
As discussed above, the cardiac AP is comprised of a well-
orchestrated ensemble of individual ion channel currents. Con-
sidering only selected ion channels for cardiac risk assessment can
therefore give a false picture, as effects of compounds on sev-
eral channels can potentiate or alleviate a potential arrhythmic
effect (Witchel et al., 2003; Fenichel et al., 2004; Moeller, 2011).
Patch-clamp recordings in cardiomyocytes have been shown to
provide a picture of the effect of compounds on the whole ensem-
ble of cardiac ion channel currents, and to reproduce the effects of
selected reference compounds on the AP. With improved proto-
cols to differentiate stem-cells of various sources into a homoge-
nous cardiomyocyte population, the availability of cardiomyocytes
increases, and the suitability of stem-cell derived cardiomyocytes
for pharmacological investigations by patch-clamping has been
convincingly demonstrated (Harding et al., 2007; Zhang et al.,
2009; Kuryshev et al., 2010; Foldes et al., 2011). Recently, stem-
cell derived cardiomyocytes from mouse have been applied to
planar patch-clamp chips, and the pharmacology of a set of refer-
ence compounds was reproduced in AP recordings (Stoelzle et al.,
2011). Also, data from human iPS-derived cardiomyocytes were
shown (Anson, 2011). This proves the potential of such recordings
and certainly represents an extremely interesting and physiolog-
ically potentially highly relevant approach. It should however be
considered that (automated) AP recordings from myocytes still
require a more thorough validation before their sensitivity and the
correlation of the data to adult cardiac physiology and pharma-
cology is better understood. In particular two potential problems
with data from stem-cell derived cardiomyocytes need to be con-
sidered: (1) Studies have given evidence that iPS and ES derived
cardiomyocytes, depending on their age, most likely represent a
neonatal state, and thus contain an ion channel population that
most likely does not represent the adult one (Binah et al., 2007; Xi
et al., 2010). This would certainly also inﬂuence the AP response
and pharmacology. (2) While stem-cell derived cardiac myocytes
certainly represent a more physiological test system than heterolo-
gous expression systems, it must be considered that in automated
patch-clamp setups the cells reside out of their physiological sur-
rounding, in (more or less) artiﬁcial buffer solutions.Also, the cells
have lost their cell–cell network contacts, and therefore require an
artiﬁcial stimulation to activate their AP.
AUTOMATED CARDIAC SAFETY ION CHANNEL PATCH-CLAMP
ELECTROPHYSIOLOGY: QUO VADIS?
The automated patch-clamp electrophysiology technology has
been referred to as an “enabling technology” for ion channel drug
discovery and research. Never before has it been practically pos-
sible for pharmaceutical companies to screen compounds on the
order of tens of thousands against an ion channel target by use of
a direct functional readout, and thus avoiding the potential false
positives and/or negatives associated to other, more indirect (such
as ﬂuorescence assay or binding techniques), high-throughput
screening methods. This has allowed drug developers to move
cardiac ion channel safety screening earlier into the drug develop-
ment pipeline, and to mitigate potential cardiac safety liabilities
of potent compound series (Davenport et al., 2010; Riether et al.,
2011; Tye et al., 2011).
The two currently known instruments with the highest rate
of parallelization and the largest throughput are – at the time
of writing this manuscript – the SyncroPatch 96 (Nanion Tech-
nologies) and the IonWorks Barracuda (MDS). While the Syn-
croPatch is capable of handling up to 96 parallel high-quality
Gigaseal recordings under continuous voltage control (using 96
well plates), the Barracuda can perform 384 parallel recordings –
albeit potentially at the price of reduced data quality or limited
voltage control, as the Barracuda relies on low-resistance seals and
employs the population patch-clamp (PPC) technology (Finkel
et al., 2006).
Furthermore, customer suggestions have led to other new
developments to the existing automated patch-clamp robots.
Recently there have been further improvements of the seal rates
and seal stabilities (e.g., by optimizing chip substrates) as well as
the addition of more sophisticated automated cell culture prepa-
rations on board of some instruments (Mathes et al., 2009).
In the future there is likely to be even further increases in
throughput, which could be achieved by an additional increase
in parallelization.
Other expected development steps concern the biological side,
as well as the pharmacological relevance of the data obtained by
automated patch-clamping: at the time of writing this manuscript,
only a few of the ampliﬁers from automated patch-clamp instru-
ments are capable of operating in current clamp mode, and thus
are able to performAP recordings from cardiomyocytes, which are
of great interest to the safety pharmacology community. Although
neither drug-induced prolongation nor triangulation of AP in car-
diac myocytes (e.g., Purkinje ﬁbers) are perfect surrogates of risk
(Gintant et al., 2001; Martin et al., 2006), if affordable and capa-
ble of high-throughput, these measures might become valuable
complementary surrogates for QT prolongation (or for the need
to provide a warning label) compared to hERG safety margins
alone (Gintant, 2011). With improved robust protocols to differ-
entiate stem-cells into cardiomyocytes, and increasing availability
of cardiomyocytes from commercial sources, we expect that more
comparative and validation data from these cells will be published.
This will certainly help the safety pharmacology community to
better assess the physiological relevance of automated AP record-
ings by patch-clamping, and evaluate the implications of these
data for safety pharmacology investigations.
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